ARTICLE
16 April 2019

Mulryne Quoted In The Pink Sheet On Brexit Ramifications For Pharmaceutical Industry

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
The article considers how UK-based life sciences companies can prepare for the UK's departure from the EU despite uncertainty surrounding the UK's unconfirmed exit deal.
United Kingdom Food, Drugs, Healthcare, Life Sciences

Life Sciences and Healthcare Regulatory partner Jacqueline Mulryne was quoted in a recent Pink Sheet article, "Pharma Uncertainty Remains As UK Votes To Delay Brexit." The article considers how UK-based life sciences companies can prepare for the UK's departure from the EU despite uncertainty surrounding the UK's unconfirmed exit deal.

» Read the full article (subscription required).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More